With your good chance of getting dementia this test should be prescribed by your doctor to establish a baseline for you. And then if found implement THOSE EXACT DEMENTIA PREVENTION PROTOCOLS your doctor should have competently already set up.
Your risk of dementia, has your doctor told you of this?
1. A documented 33% dementia chance post-stroke from an Australian study? May 2012.
2. Then this study came out and seems to have a range from 17-66%. December 2013.`
3. A 20% chance in this research. July 2013.
4. Dementia Risk Doubled in Patients Following Stroke September 2018
The latest here:
Novel 10-Minute Test Can ID Patients With Mild Cognitive Impairment, Amyloid Beta Burden
By Denise Baez
VIRTUAL -- July 29, 2021 -- A novel 10-minute battery test was able to discriminate mild cognitive impairment (MCI) from normal cognition, and identified patients with MCI with amyloid beta (Aß) burden, according to a study presented at the Virtual 2021 Alzheimer’s Association International Conference (AAIC).
“Early detection of cognitive decline is critical to improve outcomes for Alzheimer’s disease and other dementias,” said P. Monroe Butler, MD, Biogen, Cambridge, Massachusetts. “Screening for dementia risk during prodromal stages such as mild cognitive impairment typically occurs through brief, bedside cognitive measures. While these tests readily detect dementia, the relative sensitivity/specificity for identifying mild cognitive impairment is variable and the ability to predict underlying Alzheimer’s disease is poor.”
The 10-minute battery consists of the Digit-Symbol Substitution Test, the Trail Making Tests A and B, and a delayed recall task.
The test was built and validated using data from people who participated in the AD Neuroimaging Initiative Study (ADNI), the Swedish Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Study (BioFINDER), and the screening phase of aducanumab’s phase 2 EVOLVE study (before the trial was prematurely terminated). Predictors included age and APOE genotype.
Model performance was compared with the Mini-Mental State Exam (MMSE) to assess relative ability to differentiate MCI from normal cognition, and MCI with Aß burden versus without Aß burden based on imaging or fluid biomarker-based readouts of pathological Aß load.
Compared with the MMSE, the novel test showed greater sensitivity and specificity for MCI detection (area under the receiver operating characteristic curve [AUC-ROC] = 0.98 vs 0.78) and Aß prediction (AUC-ROC 0.81 vs 0.58).
“Of striking interest, removing APOE as a predictor markedly reduced accuracy in the traditional, but not in the novel 10-minute battery,” said Dr. Butler. “These preliminary data suggest that the novel combination of neuropsychological tests performed in 10 minutes may serve as a compact, more sensitive, and more specific screening tool to identify patients with MCI with amyloid beta burden compared with traditional screening batteries.”
[Presentation title: Ten-Minute Cognitive Screening Tool for Mild Cognitive Impairment and Prediction of Pathological ß-Amyloid]
VIRTUAL -- July 29, 2021 -- A novel 10-minute battery test was able to discriminate mild cognitive impairment (MCI) from normal cognition, and identified patients with MCI with amyloid beta (Aß) burden, according to a study presented at the Virtual 2021 Alzheimer’s Association International Conference (AAIC).
“Early detection of cognitive decline is critical to improve outcomes for Alzheimer’s disease and other dementias,” said P. Monroe Butler, MD, Biogen, Cambridge, Massachusetts. “Screening for dementia risk during prodromal stages such as mild cognitive impairment typically occurs through brief, bedside cognitive measures. While these tests readily detect dementia, the relative sensitivity/specificity for identifying mild cognitive impairment is variable and the ability to predict underlying Alzheimer’s disease is poor.”
The 10-minute battery consists of the Digit-Symbol Substitution Test, the Trail Making Tests A and B, and a delayed recall task.
The test was built and validated using data from people who participated in the AD Neuroimaging Initiative Study (ADNI), the Swedish Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Study (BioFINDER), and the screening phase of aducanumab’s phase 2 EVOLVE study (before the trial was prematurely terminated). Predictors included age and APOE genotype.
Model performance was compared with the Mini-Mental State Exam (MMSE) to assess relative ability to differentiate MCI from normal cognition, and MCI with Aß burden versus without Aß burden based on imaging or fluid biomarker-based readouts of pathological Aß load.
Compared with the MMSE, the novel test showed greater sensitivity and specificity for MCI detection (area under the receiver operating characteristic curve [AUC-ROC] = 0.98 vs 0.78) and Aß prediction (AUC-ROC 0.81 vs 0.58).
“Of striking interest, removing APOE as a predictor markedly reduced accuracy in the traditional, but not in the novel 10-minute battery,” said Dr. Butler. “These preliminary data suggest that the novel combination of neuropsychological tests performed in 10 minutes may serve as a compact, more sensitive, and more specific screening tool to identify patients with MCI with amyloid beta burden compared with traditional screening batteries.”
[Presentation title: Ten-Minute Cognitive Screening Tool for Mild Cognitive Impairment and Prediction of Pathological ß-Amyloid]
No comments:
Post a Comment